<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00342966</url>
  </required_header>
  <id_info>
    <org_study_id>999999032</org_study_id>
    <secondary_id>OH99-C-N032</secondary_id>
    <nct_id>NCT00342966</nct_id>
  </id_info>
  <brief_title>Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation</brief_title>
  <official_title>Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The chemopreventive efficacy of Se was tested in a 10-year human intervention trial; total&#xD;
      and lung cancer mortality, total cancer incidence, colorectal cancer and prostate cancer&#xD;
      incidence decreased. This study is designed to compare, via stable isotope tracer studies the&#xD;
      kinetics of inorganic and organic Se before and following two years of oral supplementation&#xD;
      with L-selenomethionine, to measure forms of Se in the plasma (extracellular Se-dependent&#xD;
      glutathione peroxidase [GSHPx], selenoprotein-P [SeP], albumin-bound Se [AlbSe] and&#xD;
      nonprotein-bound low molecular weight [LMWSe] fractions), and to determine the effects of&#xD;
      supplementation on the ecology of the hindgut microflora. The forms of Se were chosen to&#xD;
      resemble the metabolism of the principal forms of Se in mixed American diets. Sodium&#xD;
      selenite, an inorganic form, is metabolized by reduction to selenide which is then either&#xD;
      used in the co-translational synthesis of SeCys in specific Se-containing proteins (e.g.,&#xD;
      glutathione peroxidases, diodinases, selenoproteins P and W), or is converted to methylated&#xD;
      excretion products; in this sense it resembles the food form selenocysteine (SeCys) which is&#xD;
      metabolized to the selenide level. Selenomethionine (SeMet), an organic form, is a major form&#xD;
      of Se in many foods, particularly those of plan origin. In addition to being metabolized to&#xD;
      selenide, SeMet also enters the metabolic protein pool by competing with the&#xD;
      sulfur-containing amino acid, methionine. A study is proposed to assess the impact of&#xD;
      selenium (Se) supplementation on its metabolism in humans.&#xD;
&#xD;
      A pilot study will be conducted to test recruitment strategies and sample collection,&#xD;
      preparation and analysis and to assess the detectability of two stable isotopes given&#xD;
      together. Four subjects will receive two 300 ug oral doses consisting of 150 ug of the stable&#xD;
      isotope 76Se as selenite and 150 ug of the stable isotope 74Se as selenomethionine on study&#xD;
      days one and twelve. Subjects will be followed for six weeks.&#xD;
&#xD;
      In the first pharmacokinetics tracer study (PK1), twenty-eight subjects will receive the same&#xD;
      two labeled stable isotope doses, and will be followed for 4 months. In addition, two&#xD;
      subjects who have been self-supplementing with 200 ug of Se as selenized yeast for two years&#xD;
      will take part in PK1 to assess the sensitivity over time of the tracer assay in supplemented&#xD;
      subjects. PK1 will be followed by a 2-yr supplementation period, in which all 28 subjects&#xD;
      will receive daily doses of 200 ug of L0SeMet; subjects = metabolism is expected to approach&#xD;
      a new steady state reflective of long-term supplementation. A second 4-month pharmacokinetic&#xD;
      tracer study (PK2) will then be conducted while subjects remain on Se-supplementation with an&#xD;
      extension of six monthly blood samples. Extensive sampling of plasma, urine, and feces during&#xD;
      PK1 and PK2 will permit both the refinement of existing baseline models for selenite and&#xD;
      selenomethionine metabolism in humans and the investigation of changes in metabolism arising&#xD;
      from Se-supplementation. The study is designed to detect a difference of 0.75 standard&#xD;
      deviation units in pre-versus post-supplementation rate parameters, assuming a two-sided test&#xD;
      with an alpha level of 0.05 and a power of 0.80.&#xD;
&#xD;
      The non-absorbed portion of Se may favor portions of the normal colonic bacterial microflora&#xD;
      that produce certain short-chain fatty acids that colon cells use for energy. To test this&#xD;
      hypothesis, fecal specimens will be analyzed for short-chain fatty acids over the course of&#xD;
      Se-supplementation. In addition, the sampling of buccal cell-Se and of toenail-Se on a&#xD;
      quarterly basis over the course of the study and assay of thyroid hormone levels during the&#xD;
      first year of the study will permit the investigation of possible changes in levels resulting&#xD;
      from supplementation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The chemopreventive efficacy of Se was tested in a 10-year human intervention trial; total&#xD;
      and lung cancer mortality, total cancer incidence, colorectal cancer and prostate cancer&#xD;
      incidence decreased. This study is designed to compare, via stable isotope tracer studies the&#xD;
      kinetics of inorganic and organic Se before and following two years of oral supplementation&#xD;
      with L-selenomethionine, to measure forms of Se in the plasma (extracellular Se-dependent&#xD;
      glutathione peroxidase [GSHPx], selenoprotein-P [SeP], albumin-bound Se [AlbSe] and&#xD;
      nonprotein-bound low molecular weight [LMWSe] fractions), and to determine the effects of&#xD;
      supplementation on the ecology of the hindgut microflora. The forms of Se were chosen to&#xD;
      resemble the metabolism of the principal forms of Se in mixed American diets. Sodium&#xD;
      selenite, an inorganic form, is metabolized by reduction to selenide which is then either&#xD;
      used in the co-translational synthesis of SeCys in specific Se-containing proteins (e.g.,&#xD;
      glutathione peroxidases, diodinases, selenoproteins P and W), or is converted to methylated&#xD;
      excretion products; in this sense it resembles the food form selenocysteine (SeCys) which is&#xD;
      metabolized to the selenide level. Selenomethionine (SeMet), an organic form, is a major form&#xD;
      of Se in many foods, particularly those of plan origin. In addition to being metabolized to&#xD;
      selenide, SeMet also enters the metabolic protein pool by competing with the&#xD;
      sulfur-containing amino acid, methionine. A study is proposed to assess the impact of&#xD;
      selenium (Se) supplementation on its metabolism in humans.&#xD;
&#xD;
      A pilot study will be conducted to test recruitment strategies and sample collection,&#xD;
      preparation and analysis and to assess the detectability of two stable isotopes given&#xD;
      together. Four subjects will receive two 300 ug oral doses consisting of 150 ug of the stable&#xD;
      isotope 76Se as selenite and 150 ug of the stable isotope 74Se as selenomethionine on study&#xD;
      days one and twelve. Subjects will be followed for six weeks.&#xD;
&#xD;
      In the first pharmacokinetics tracer study (PK1), twenty-eight subjects will receive the same&#xD;
      two labeled stable isotope doses, and will be followed for 4 months. In addition, two&#xD;
      subjects who have been self-supplementing with 200 ug of Se as selenized yeast for two years&#xD;
      will take part in PK1 to assess the sensitivity over time of the tracer assay in supplemented&#xD;
      subjects. PK1 will be followed by a 2-yr supplementation period, in which all 28 subjects&#xD;
      will receive daily doses of 200 ug of L0SeMet; subjects = metabolism is expected to approach&#xD;
      a new steady state reflective of long-term supplementation. A second 4-month pharmacokinetic&#xD;
      tracer study (PK2) will then be conducted while subjects remain on Se-supplementation with an&#xD;
      extension of six monthly blood samples. Extensive sampling of plasma, urine, and feces during&#xD;
      PK1 and PK2 will permit both the refinement of existing baseline models for selenite and&#xD;
      selenomethionine metabolism in humans and the investigation of changes in metabolism arising&#xD;
      from Se-supplementation. The study is designed to detect a difference of 0.75 standard&#xD;
      deviation units in pre-versus post-supplementation rate parameters, assuming a two-sided test&#xD;
      with an alpha level of 0.05 and a power of 0.80.&#xD;
&#xD;
      The non-absorbed portion of Se may favor portions of the normal colonic bacterial microflora&#xD;
      that produce certain short-chain fatty acids that colon cells use for energy. To test this&#xD;
      hypothesis, fecal specimens will be analyzed for short-chain fatty acids over the course of&#xD;
      Se-supplementation. In addition, the sampling of buccal cell-Se and of toenail-Se on a&#xD;
      quarterly basis over the course of the study and assay of thyroid hormone levels during the&#xD;
      first year of the study will permit the investigation of possible changes in levels resulting&#xD;
      from supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 14, 1999</start_date>
  <completion_date>July 23, 2010</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Cancer</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Those subjects with normal physical examinations and Se plasma levels within the eligible&#xD;
        range will be invited to participate in the study.&#xD;
&#xD;
        Men and women will be recruited according to the following eligibility criteria. Subjects&#xD;
        must:&#xD;
&#xD;
        be between the ages of 20 and 60 years;&#xD;
&#xD;
        be in general good health as determined by a screening history and physical examination and&#xD;
        laboratory tests with no history of gastrointestinal, hepatic, renal and/or hematologic&#xD;
        diseases, cancer, coronary heart disease;&#xD;
&#xD;
        be within 20% from their ideal weight as described in the Metlife Height and Weight Tables&#xD;
        (1993);&#xD;
&#xD;
        be consuming typical mixed diets;&#xD;
&#xD;
        give informed consent; and&#xD;
&#xD;
        be judged, based on a personal interview, as having a high probability of participating for&#xD;
        the two-year eight month duration of the study.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        women: pregnant or lactating women; sexually active and not using contraceptives (e.g.,&#xD;
        condoms, oral contraceptives, diaphragm); planning to become pregnant during the&#xD;
        experimental period; or post -menopausal (at least 6 months);&#xD;
&#xD;
        taking antibiotics on a regular basis;&#xD;
&#xD;
        have a history of taking Se supplements of more than 25 ug/d in the past year;&#xD;
&#xD;
        current smoker, or stopped smoking within the last 6 months;&#xD;
&#xD;
        on rigorous exercise or weight-reduction programs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USDA</name>
      <address>
        <city>Beltsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute (NCI), 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ankerst J, Sj√∂gren HO. Effect of selenium on the induction of breast fibroadenomas by adenovirus type 9 and 1,2-dimethylhydrazine-induced bowel carcinogenesis in rats. Int J Cancer. 1982 Jun 15;29(6):707-10.</citation>
    <PMID>7107071</PMID>
  </reference>
  <reference>
    <citation>Bergad PL, Rathbun WB. Inhibition of Na,K-ATPase by sodium selenite and reversal by glutathione. Curr Eye Res. 1986 Dec;5(12):919-23.</citation>
    <PMID>3026732</PMID>
  </reference>
  <reference>
    <citation>Birt DF, Julius AD, Runice CE, White LT, Lawson T, Pour PM. Enhancement of BOP-induced pancreatic carcinogenesis in selenium-fed Syrian golden hamsters under specific dietary conditions. Nutr Cancer. 1988;11(1):21-33.</citation>
    <PMID>2832833</PMID>
  </reference>
  <verification_date>July 23, 2010</verification_date>
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Metabolism</keyword>
  <keyword>Tracer Studies</keyword>
  <keyword>Chemoprevention</keyword>
  <keyword>Selenomethionine</keyword>
  <keyword>Plasma Selenoproteins</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

